Lung cancer

Daniel R. Gomez; Heng Li; Xiaodong Zhang; Joe Y. Chang; Zhongxing Liao; Steven H. Lin

doi:10.1016/B978-0-323-73349-6.00027-3

Lung cancer

Daniel R. Gomez, Heng Li, Xiaodong Zhang, Joe Y. Chang, Zhongxing Liao, Steven H. Lin

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Proton therapy for lung cancer has been demonstrated to have dosimetric advantages over photon therapies in treatment plan comparisons, but the clinical evidence is still relatively limited, as are potential criteria to identify which patients would benefit (or not benefit) from proton therapy. This chapter reviews known indications for passive scattering versus intensity-modulated proton therapy for lung cancer and touches on issues associated with treatment simulation, choice of radiation dose and fractionation schedule, target delineation, treatment verification, and treatment planning for proton therapy. Also discussed are the clinical outcomes of proton therapy for early-stage or locally advanced disease published to date.

Original language	English (US)
Title of host publication	Proton Therapy
Subtitle of host publication	Indications, Techniques and Outcomes
Publisher	Elsevier
Pages	205-214.e4
ISBN (Electronic)	9780323733496
ISBN (Print)	9780323733502
DOIs	https://doi.org/10.1016/B978-0-323-73349-6.00027-3
State	Published - Jan 1 2020

Keywords

intensity-modulated proton therapy
motion management
passive scattering proton therapy
tissue heterogeneity

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-73349-6.00027-3

Cite this

@inbook{f479848e7d8d4072914b25ac3d9acb4c,

title = "Lung cancer",

abstract = "Proton therapy for lung cancer has been demonstrated to have dosimetric advantages over photon therapies in treatment plan comparisons, but the clinical evidence is still relatively limited, as are potential criteria to identify which patients would benefit (or not benefit) from proton therapy. This chapter reviews known indications for passive scattering versus intensity-modulated proton therapy for lung cancer and touches on issues associated with treatment simulation, choice of radiation dose and fractionation schedule, target delineation, treatment verification, and treatment planning for proton therapy. Also discussed are the clinical outcomes of proton therapy for early-stage or locally advanced disease published to date.",

keywords = "intensity-modulated proton therapy, motion management, passive scattering proton therapy, tissue heterogeneity",

author = "Gomez, {Daniel R.} and Heng Li and Xiaodong Zhang and Chang, {Joe Y.} and Zhongxing Liao and Lin, {Steven H.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-73349-6.00027-3",

language = "English (US)",

isbn = "9780323733502",

pages = "205--214.e4",

booktitle = "Proton Therapy",

publisher = "Elsevier",

}

TY - CHAP

T1 - Lung cancer

AU - Gomez, Daniel R.

AU - Li, Heng

AU - Zhang, Xiaodong

AU - Chang, Joe Y.

AU - Liao, Zhongxing

AU - Lin, Steven H.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Proton therapy for lung cancer has been demonstrated to have dosimetric advantages over photon therapies in treatment plan comparisons, but the clinical evidence is still relatively limited, as are potential criteria to identify which patients would benefit (or not benefit) from proton therapy. This chapter reviews known indications for passive scattering versus intensity-modulated proton therapy for lung cancer and touches on issues associated with treatment simulation, choice of radiation dose and fractionation schedule, target delineation, treatment verification, and treatment planning for proton therapy. Also discussed are the clinical outcomes of proton therapy for early-stage or locally advanced disease published to date.

AB - Proton therapy for lung cancer has been demonstrated to have dosimetric advantages over photon therapies in treatment plan comparisons, but the clinical evidence is still relatively limited, as are potential criteria to identify which patients would benefit (or not benefit) from proton therapy. This chapter reviews known indications for passive scattering versus intensity-modulated proton therapy for lung cancer and touches on issues associated with treatment simulation, choice of radiation dose and fractionation schedule, target delineation, treatment verification, and treatment planning for proton therapy. Also discussed are the clinical outcomes of proton therapy for early-stage or locally advanced disease published to date.

KW - intensity-modulated proton therapy

KW - motion management

KW - passive scattering proton therapy

KW - tissue heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85142055887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142055887&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-73349-6.00027-3

DO - 10.1016/B978-0-323-73349-6.00027-3

M3 - Chapter

AN - SCOPUS:85142055887

SN - 9780323733502

SP - 205-214.e4

BT - Proton Therapy

PB - Elsevier

ER -

Lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this